Peringkat dalam Saham
#40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Harga Saham
$0.00162013
Terakhir disinkronkan: 2025-01-03
Kapitalisasi Pasar
$156.25K
Perubahan (1 tahun)
0.00%
Perdagangan Cyxone AB (publ) (CYXO)
Harga CYXO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Cyxone AB (publ)(CYXO)
Kapitalisasi Pasar: $156.25K
Per August 2026, Cyxone AB (publ) memiliki kapitalisasi pasar sebesar $156.25K. Ini menjadikan Cyxone AB (publ) sebagai perusahaan 40403rd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Cyxone AB (publ) dari 2016 hingga 2026
CYXO dibandingkan dengan 5 teratas stocks paling populer
| Harga CYXO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.470T
|
+3,500,444,002.38%
|
|
|
|
|
$4.467T
|
+2,858,876,405.30%
|
|
|
|
|
$4.174T
|
+2,671,561,324.47%
|
|
|
|
|
$3.700T
|
+2,368,008,737.69%
|
|
|
|
|
$2.854T
|
+1,826,747,876.55%
|
